摘 要：摘 要：作为造血干/祖细胞(hematopoietic stem cells/hematopoietic progenitor cells, HSCs/HPCs)的另一来源，脐带血已经应用于临床治疗多种恶性和非恶性疾病。脐带血中HSCs/HPCs的质与量是决定其临床应用效果的最重要因素。同时，脐带血中还存在多种非造血的干细胞和前体细胞，如间充质干细胞(mesenchymal stem cells, MSCs)、内皮前体细胞(endothelial progenitor cells, EPCs)和非限制性体干细胞(unrestricted somatic stem cells, USSCs)等，这些细胞可能会在未来的细胞治疗和再生医学中发挥重要作用。本综述还讨论了脐带血的临床应用及HSCs/HPCs的体外扩增、增加HSCs归巢和再植能力等提高其临床应用能力的相关研究。
关键词：脐带血；造血干细胞；移植
Abstract: Abstract: Umbilical cord blood (UCB), as an alternative source of hematopoietic/progenitor stem cells (HSCs/HPCs), has been used clinically for a large number of malignant and non-malignant disorders. The quality and quantity of HSC and HPC may be the most important factors on which the capacity of UCB to perform clinical function depends. Other non-HSCs/HPCs, such as mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and unrestricted somatic stem cells (USSCs), also present in cord blood, which may play a future role in cell therapy and regenerative medicine. This review also covers the efforts to expand HSCs and HPCs ex vivo and recent studies on attempts to enhance the homing and engrafting capability of HSCs as means to enhance the clinical utility of UCB.
Key words: umbilical cord blood; hematopoietic stem cells; transplantation
